Poly Medicure opened lower at ₹1,630.00, compared with its previous close of ₹1,641.20. During today's session, the stock has traded between ₹1,596.00 and ₹1,630.00, with an average traded price of ₹1,607.10. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Poly Medicure is now worth
₹ 16,485.00
giving a profit of
₹ 6,485.00 (64.85%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-41.20 (-2.51%)
Day High
₹1,630.00
Day Low
₹1,596.00
Day Open
₹1,630.00
Prev Close
₹1,641.20
Volume
77,984
Value Traded
₹12.53 Cr
1W Return
-1.21%
1M Return
-7.97%
3M Return
-4.09%
6M Return
9.42%
1Y Return
-15.61%
Market Cap (₹ Cr.)
16,218
PE Ratio
53.30
PB Ratio
5.36
Dividend Yield
0.21%
ROE
10.18%
ROCE
13.33%
Book Value (₹)
306.45
Face Value (₹)
5.00
EPS (TTM)
8.49
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-1.21%
6 Week
-
1 Month
-7.97%
3 Month
-4.09%
9 Month
-8.68%
Medicure completes enrollment in MEND-PNPO Phase 3 trial
Medicure completed enrollment of 10 patients in its MEND-PNPO Phase 3 trial. MC-1 holds FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations. Company eligible for Priority Review Voucher upon NDA approval. Baseline data presented at European Epilepsy Congress; further presentations scheduled.
14 days agoPoly Medicure closes trading window ahead of Q2FY27 results
Trading window closed from October 1, 2026. Closure lasts until 48 hours after Q2FY27 results declaration. Compliance with SEBI insider trading regulations cited. Board meeting date for results to be announced later.
15 days agoPoly Medicure schedules investor meet with Avendus Spark on Sept 30
Poly Medicure Limited to meet Avendus Spark on September 30, 2026. Meeting scheduled for 10:00 am at Ballabgarh plant in Haryana. Interaction is a one-on-one format including a plant visit. No unpublished price sensitive information will be disclosed.
19 days agoPoly Medicure schedules analyst meet with ICICI Securities on Sep 24
Poly Medicure holds one-on-one meet with ICICI Securities PMS. Meeting scheduled for September 24, 2026, at 4:00 pm. Venue is the company's registered office in New Delhi. Disclosure made under SEBI LODR Regulation 30.
22 days agoPoly Medicure schedules investor meet with Axis Max Life on Sep 23
Poly Medicure to hold one-on-one meet with Axis Max Life. Session scheduled for September 23, 2026 at 4:00 pm. Meeting format is virtual as per SEBI LODR norms. No unpublished price-sensitive info to be shared.
25 days agoMedicure presents MEND-PNPO Phase 3 study data at European Epilepsy Congress
Medicure presents MEND-PNPO Phase 3 design and baseline data at European Epilepsy Congress. Nine patients enrolled in trial evaluating MC-1 for PNPO deficiency; three completed one-year study. Baseline P5P levels ranged from 59.8 to 165 ng/mL among participants. Study aims to enroll approximately 10 patients aged 2 years and older. Company plans further presentations at North American neurology meetings in late 2026.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹336.75 | +1.89% | ₹1,791.72 | 158.06 | +12.81% | |
| ₹601.75 | -0.50% | ₹1,403.77 | 25.31 | +75.44% | |
| ₹195.94 | +0.12% | ₹1,078.25 | 34.93 | -38.46% | |
| ₹460.05 | -2.26% | ₹804.79 | 72.30 | -21.71% | |
| ₹360.20 | +0.92% | ₹640.96 | 21.74 | -41.89% | |
| ₹137.03 | +4.41% | ₹609.11 | 12.00 | -29.67% | |
| ₹178.87 | -2.81% | ₹345.89 | 28.27 | +67.72% | |
| ₹323.40 | -2.41% | ₹308.59 | 73.19 | +39.20% | |
| ₹97.85 | -10.23% | ₹186.31 | 40.52 | -60.13% | |
| ₹170.00 | -3.95% | ₹178.73 | 20.70 | -37.04% | |
| ₹31.30 | -0.16% | ₹57.08 | -3.43 | +0.00% | |
| ₹60.10 | +0.02% | ₹30.29 | 5.47 | -7.54% |
An investment of ₹10,000 made 5 years ago in Poly Medicure is now worth
₹ 16,485.00
giving a profit of
₹ 6,485.00 (64.85%)
Note: Past profits do not guarantee future returns.
